For the new therapy, these cells are derived from stem cells that originated from healthy adult donor tissue - called induced pluripotent stem cells (iPSCs) - to make therapeutic CAR-NK cells.

The Cambridge, Massachusetts-based biotech is the latest player in the emerging field of chimeric antigen receptor (CAR) NK cell therapies, which unlike the current generation of CAR-T therapies ...